16 results on '"Marieke J. Pierik"'
Search Results
2. Early infliximab trough levels in paediatric IBD patients predict sustained remission
- Author
-
Nanja Bevers, Arta Aliu, Dennis R. Wong, Bjorn Winkens, Anita Vreugdenhil, Marieke J. Pierik, Luc J. J. Derijks, and Patrick F. van Rheenen
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background: Exposure–response studies have shown that higher infliximab concentrations are associated with better outcomes in inflammatory bowel disease. There is little agreement about the optimal time to measure infliximab levels in children. Objectives: We aimed to evaluate whether trough levels at week 6 or week 14 predict sustained remission. The secondary aim was to define target trough levels at weeks 6 and 14. Design: We used routinely collected electronic healthcare data of 70 anti-tumour necrosis factor naïve children with inflammatory bowel disease treated with a standard infliximab induction- and variable maintenance scheme. Methods: Trough levels and blood and faecal markers for disease activity were measured before every infliximab administration. Sustained remission was defined as the absence of symptoms and low inflammatory markers between weeks 26 and 52 after the start of infliximab therapy. Optimal infliximab levels at weeks 6 and 14 were determined using the receiver operating characteristic curve. Results: The median infliximab level at week 6 was not significantly higher in children who achieved sustained remission compared to those who did not (16.9 mg/L versus 12.0 mg/L; p = 0.058) but the median infliximab level at week 14 was significantly higher in those with sustained remission (7.7 mg/L versus 3.8 mg/L; p = 0.006). The area under the receiver operating characteristics curves at weeks 6 and 14 to predict sustained remission was 0.67 (95% CI 0.51–0.83) and 0.75 (95% CI 0.60–0.90), respectively. Target trough levels at weeks 6 and 14 were ⩾13.2 and ⩾6.9 mg/L, respectively. Conclusion: An infliximab measurement at week 14 with a target through level ⩾6.9 mg/L best predicted sustained remission.
- Published
- 2024
- Full Text
- View/download PDF
3. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options
- Author
-
Arno R. Bourgonje, Reinier C. A. van Linschoten, Rachel L. West, Maarten A. van Dijk, Coretta C. van Leer-Buter, Gursah Kats-Ugurlu, Marieke J. Pierik, Eleonora A. M. Festen, Rinse K. Weersma, and Gerard Dijkstra
- Subjects
Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
In the wake of the coronavirus disease 2019 (COVID-19) pandemic, it is unclear how asymptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected patients who present with acute severe ulcerative colitis (UC) can be treated effectively and safely. Standard treatment regimens consist of steroids, immunomodulatory drugs, and biological therapies, but therapeutic decision-making becomes challenging as there are uncertainties about how to deal with these drugs in patients with COVID-19 and active UC. Importantly, guidelines for this particular group of patients with UC are still lacking. To inform therapeutic decision-making, we describe three consecutive cases of patients with active UC and COVID-19 and discuss their treatments based on theoretical knowledge, currently available evidence and clinical observations. Three patients were identified through our national inflammatory bowel disease network [Initiative on Crohn’s and Colitis (ICC)] for whom diagnosis of SARS-CoV-2-infection was established by reverse transcription–polymerase chain reaction (RT-PCR) testing in nasopharynx, stools, and/or biopsies. Acute severe UC was diagnosed by clinical parameters, endoscopy, and histopathology. Clinical guidelines for SARS-CoV-2-negative patients advocate the use of steroids, calcineurin inhibitors, or tumor necrosis factor alpha (TNF-α)-antagonists as induction therapy, and experiences from the current three cases show that steroids and TNF-α-antagonists could also be used in patients with COVID-19. This could potentially be followed by TNF-α-antagonists, vedolizumab, or ustekinumab as maintenance therapy in these patients. Future research is warranted to investigate if, and which, immunomodulatory drugs should be used for COVID-19 patients that present with active UC. To answer this question, it is of utmost importance that future cases of patients with UC and COVID-19 are documented carefully in international registries, such as the SECURE-IBD registry.
- Published
- 2021
- Full Text
- View/download PDF
4. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
- Author
-
Yukihide Momozawa, Julia Dmitrieva, Emilie Théâtre, Valérie Deffontaine, Souad Rahmouni, Benoît Charloteaux, François Crins, Elisa Docampo, Mahmoud Elansary, Ann-Stephan Gori, Christelle Lecut, Rob Mariman, Myriam Mni, Cécile Oury, Ilya Altukhov, Dmitry Alexeev, Yuri Aulchenko, Leila Amininejad, Gerd Bouma, Frank Hoentjen, Mark Löwenberg, Bas Oldenburg, Marieke J. Pierik, Andrea E. vander Meulen-de Jong, C. Janneke van der Woude, Marijn C. Visschedijk, The International IBD Genetics Consortium, Mark Lathrop, Jean-Pierre Hugot, Rinse K. Weersma, Martine De Vos, Denis Franchimont, Severine Vermeire, Michiaki Kubo, Edouard Louis, and Michel Georges
- Subjects
Science - Abstract
Most of the more than 200 known genetic risk loci for inflammatory bowel disease (IBD) reside in regulatory regions. Here, the authors provide eQTL datasets for six circulating immune cell types and ileal, colonic and rectal biopsies to map regulatory modules and identify potential causative genes for IBD.
- Published
- 2018
- Full Text
- View/download PDF
5. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
- Author
-
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N Bernstein, Gilaad G Kaplan, Dana Duricova, Dan Greenberg, Hans O Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valérie E H Pittet, Vito Annese, KT Park, Konstantinos H Katsanos, Marte L Høivik, Zeljko Krznaric, María Chaparro, Edward V Loftus, Peter L Lakatos, Javier P Gisbert, Willem Bemelman, Bjorn Moum, Richard B Gearry, Michael D Kappelman, Ailsa Hart, Marieke J Pierik, Jane M Andrews, Siew C Ng, Renata D'Inca, and Pia Munkholm
- Subjects
Hepatology ,Gastroenterology - Abstract
The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease and ulcerative colitis in both developed and newly industrialised countries, but also the chronic nature of the diseases, the need for long-term, often expensive treatments, the use of more intensive disease monitoring strategies, and the effect of the diseases on economic productivity. This Commission draws together a wide range of expertise to discuss the current costs of IBD care, the drivers of increasing costs, and how to deliver affordable care for IBD in the future. The key conclusions are that (1) increases in health-care costs must be evaluated against improved disease management and reductions in indirect costs, and (2) that overarching systems for data interoperability, registries, and big data approaches must be established for continuous assessment of effectiveness, costs, and the cost-effectiveness of care. International collaborations should be sought out to evaluate novel models of care (eg, value-based health care, including integrated health care, and participatory health-care models), as well as to improve the education and training of clinicians, patients, and policy makers.
- Published
- 2023
6. Predictive Algorithm for Thiopurine-Induced Hepatotoxicity in Inflammatory Bowel Disease Patients
- Author
-
Sofia A. W. van Moorsel, Debbie S. Deben, Rob H. Creemers, Bjorn Winkens, Paul Bus, Marieke J. Pierik, Melek Simsek, Nanne K. H. de Boer, Adriaan A. van Bodegraven, Dennis R. Wong, Interne Geneeskunde, RS: NUTRIM - R2 - Liver and digestive health, FHML Methodologie & Statistiek, RS: CAPHRI - R6 - Promoting Health & Personalised Care, MUMC+: MA Maag Darm Lever (9), Gastroenterology and hepatology, and Amsterdam Gastroenterology Endocrinology Metabolism
- Subjects
Pharmacology ,Drug-Related Side Effects and Adverse Reactions ,Mercaptopurine ,Azathioprine ,Humans ,Pharmacology (medical) ,Chemical and Drug Induced Liver Injury ,Inflammatory Bowel Diseases ,Algorithms ,Immunosuppressive Agents - Abstract
BACKGROUND: Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathioprine (AZA) or mercaptopurine (MP) therapy within 3 months of treatment initiation due to adverse drug reactions. Of these side-effects, about half are due to hepatotoxicity.The aim of this study was to validate and (subsequently) optimize a previously reported predictive algorithm for thiopurine-associated hepatotoxicity by increasing the number of patients with IBD benefitting from conventional thiopurine therapy.METHODS: This multicenter observational study included consecutive thiopurine-naive patients with IBD who received AZA or MP treatment. The primary outcome was hepatotoxicity within 12 weeks. The patients with and without hepatotoxicity were compared. Four determinants, namely, age, sex, body mass index (BMI), and 6-methylmercaptopurine ribonucleotide (6-MMPR) concentrations 1 week after treatment initiation (T = 1) were used to validate and optimize two (one dichotomous and one continuous) algorithms using multivariable logistic regression analysis.RESULTS: Of 229 patients, 21 (9%) developed hepatotoxicity and 93% of the patients received MP with a median dose of 0.7 mg/kg (95% CI 0.3-1.4 mg/kg). A difference in BMI was found between with and without hepatotoxicity groups (median 27.6 versus 24.2, p = 0.022). Specificities of 68% (Algorithm 1) and 77% (Algorithm 2) and sensitivities of 56% (Algorithm 1) and 50% (Algorithm 2) were obtained.CONCLUSION: Both algorithms demonstrated limited predictive accuracy for thiopurine-induced hepatotoxicity in the validation cohort. Relevant factors contributing to this outcome were changes in thiopurine prescription behavior over time, with more MP prescriptions at relatively lower dosages of MP.
- Published
- 2022
7. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis
- Author
-
Marc, Ferrante, Anja, Schirbel, Marieke J, Pierik, Thomas, Haas, Mathurin, Flamant, Ahmed, Khalifa, George, Philip, Freddy, Cornillie, Alan G, Meehan, Marinella, Govoni, Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), and RS: NUTRIM - R2 - Liver and digestive health
- Subjects
Adult ,moderate-to ,Hepatology ,Mayo score ,Remission Induction ,Gastroenterology ,Antibodies, Monoclonal ,REMISSION ,severe ulcerative colitis ,Severity of Illness Index ,Treatment Outcome ,Humans ,Colitis, Ulcerative ,Patient Reported Outcome Measures ,Prospective Studies ,golimumab ,Gastrointestinal Hemorrhage - Abstract
BACKGROUND: In PURSUIT, golimumab (GLM) was efficacious in patients with moderate-to-severe ulcerative colitis (UC). We assessed whether remote monitoring of combined patient-reported Mayo stool frequency and rectal bleeding scores is an effective real-world outcome measure for assessing maintenance of GLM-induced clinical response.METHODS: This was a 54-week prospective, observational cohort study conducted at 43 European outpatient clinics in adults with moderate-to-severe UC who were biologic naïve or had received a maximum of one other biological therapy. Patients were treated according to European GLM UC label/local practice. Clinical response (based on partial or full Mayo score) was assessed at week 6, 10, or 14 of induction, depending on local practice. Investigators remotely monitored scores every 4 weeks. The primary endpoint was the proportion of induction responders in patient-reported continuous clinical response (pCCR) at week 54, defined as absence of UC flare based on combined patient-reported Mayo stool frequency and rectal bleeding scores every 4 weeks and full or partial Mayo score. A key secondary endpoint was the proportion of induction responders in clinical remission at week 54.RESULTS: Among 109 patients, 37 (34.0%) received at least two GLM induction doses and completed induction in clinical response (induction responders). At week 54, 15/37 (40.5%) induction responders were in pCCR, and 21/37 (56.8%) were in clinical remission.CONCLUSION: In daily clinical practice, regular remote monitoring of combined patient-reported Mayo stool frequency and rectal bleeding scores appears to be a meaningful real-world outcome measure for monitoring maintenance of GLM-induced clinical response in UC.
- Published
- 2022
8. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial
- Author
-
Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch, Gastroenterology and hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, and Gastroenterology & Hepatology
- Subjects
All institutes and research themes of the Radboud University Medical Center ,Hepatology ,Gastroenterology ,Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0] ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Analytical Chemistry ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] - Abstract
Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab dose intervals versus conventional dosing in patients with Crohn's disease in stable remission. METHODS: The LADI study was a pragmatic, open-label, multicentre, non-inferiority, parallel, randomised controlled trial, done in six academic hospitals and 14 general hospitals in the Netherlands. Adults (aged ≥18 years) diagnosed with luminal Crohn's disease (with or without concomitant perianal disease) were eligible when in steroid-free clinical and biochemical remission (defined as Harvey-Bradshaw Index [HBI] score
- Published
- 2023
9. The Intake of Dicarbonyls and Advanced Glycation Endproducts as Part of the Habitual Diet Is Not Associated with Intestinal Inflammation in Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients
- Author
-
Marlijne C. G. de Graaf, Jean L. J. M. Scheijen, Corinne E. G. M. Spooren, Zlatan Mujagic, Marieke J. Pierik, Edith J. M. Feskens, Daniel Keszthelyi, Casper G. Schalkwijk, Daisy M. A. E. Jonkers, Interne Geneeskunde, RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, MUMC+: MA Alg Onderzoek Interne Geneeskunde (9), RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Maag Darm Lever (9), and Bedrijfsbureau NTM
- Subjects
Global Nutrition ,irritable bowel syndrome ,Wereldvoeding ,Nutrition and Dietetics ,dietary dicarbonyls ,Lysine ,faecal calprotectin ,Glycation End Products ,Irritable Bowel Syndrome/complications ,Pyruvaldehyde ,Inflammation/complications ,Inflammatory Bowel Diseases/complications ,Diet/adverse effects ,inflammatory bowel disease ,dietary advanced glycation endproducts ,intestinal inflammation ,Humans ,Glycation End Products, Advanced/adverse effects ,Advanced/adverse effects ,Food Science ,VLAG - Abstract
A Western diet comprises high levels of dicarbonyls and advanced glycation endproducts (AGEs), which may contribute to flares and symptoms in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). We therefore investigated the intake of dietary dicarbonyls and AGEs in IBD and IBS patients as part of the habitual diet, and their association with intestinal inflammation. Food frequency questionnaires from 238 IBD, 261 IBS as well as 195 healthy control (HC) subjects were used to calculate the intake of dicarbonyls methylglyoxal, glyoxal, and 3-deoxyglucosone, and of the AGEs Nε-(carboxymethyl)lysine, Nε-(1-carboxyethyl)lysine and methylglyoxal-derived hydroimidazolone-1. Intestinal inflammation was assessed using faecal calprotectin. The absolute dietary intake of all dicarbonyls and AGEs was higher in IBD and HC as compared to IBS (all p < 0.05). However, after energy-adjustment, only glyoxal was lower in IBD versus IBS and HC (p < 0.05). Faecal calprotectin was not significantly associated with dietary dicarbonyls and AGEs in either of the subgroups. The absolute intake of methylglyoxal was significantly higher in patients with low (
- Published
- 2023
10. Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial
- Author
-
Nanja Bevers, Els Van de Vijver, Arta Aliu, Ashkan Rezazadeh Ardabili, Philippe Rosias, Janneke Stapelbroek, Imke A. Bertrams Maartens, Cathelijne van de Feen, Hankje Escher, Annemarie Oudshoorn, Sarah Teklenburg, Saskia Vande Velde, Bjorn Winkens, Maarten Raijmakers, Anita Vreugdenhil, Marieke J. Pierik, Patrick F. van Rheenen, Interne Geneeskunde, RS: NUTRIM - R2 - Liver and digestive health, FHML Methodologie & Statistiek, RS: CAPHRI - R6 - Promoting Health & Personalised Care, Kindergeneeskunde, MUMC+: MA Medische Staf Kindergeneeskunde (9), RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, MUMC+: MA Maag Darm Lever (9), Pediatrics, and Center for Liver, Digestive and Metabolic Diseases (CLDM)
- Subjects
Iron-deficiency anemia ,6-minute walk test ,Oral iron ,Efficacy ,Diagnosis ,Validation ,Pediatrics, Perinatology and Child Health ,Medicine and Health Sciences ,Prevalence ,Human medicine ,Safety ,Pediatric gastroenterology ,Management - Abstract
Objective: To determine whether intravenous (IV) or oral iron suppletion is superior in improving physical fitness in anemic children with inflammatory bowel disease (IBD). Study design: We conducted a clinical trial at 11 centers. Children aged 8 to 18 with IBD and anemia (defined as hemoglobin (Hb) z-score < -2) were randomly assigned to a single IV dose of ferric carboxymaltose or 12 weeks of oral ferrous fumarate. Primary endpoint was the change in 6-minute walking distance (6MWD) from baseline, expressed as z-score. Secondary outcome was a change in Hb z-score from baseline. Results: We randomized 64 patients (33 IV iron; 31 oral iron) and followed them for 6 months. One month after the start of iron therapy, the 6MWD z-score of patients in the IV group had increased by 0.71 compared with -0.11 in the oral group (P=0.01). At 3- and 6-months follow-up, no significant differences in 6MWD z-scores were observed. Hb z-scores gradually increased in both groups and the rate of increase was not different between groups at 1, 3 and 6 months after initiation of iron therapy (overall P=0.97). Conclusion: In this trial involving anemic children with IBD, a single dose of IV ferric carboxymaltose was superior to oral ferrous fumarate with respect to quick improvement of physical fitness. At 3 and 6 months after initiation of therapy, no differences were discovered between oral or IV therapy. The increase of Hb over time was comparable in both treatment groups. Trial registration: NTR4487 [Netherlands Trial Registry]. Keywords: Crohn’s disease; Ulcerative Colitis; anemia; children; iron suppletion.
- Published
- 2023
11. The effect of sampling and storage on the fecal microbiota composition in healthy and diseased subjects.
- Author
-
Danyta I Tedjo, Daisy M A E Jonkers, Paul H Savelkoul, Ad A Masclee, Niels van Best, Marieke J Pierik, and John Penders
- Subjects
Medicine ,Science - Abstract
Large-scale cohort studies are currently being designed to investigate the human microbiome in health and disease. Adequate sampling strategies are required to limit bias due to shifts in microbial communities during sampling and storage. Therefore, we examined the impact of different sampling and storage conditions on the stability of fecal microbial communities in healthy and diseased subjects. Fecal samples from 10 healthy controls, 10 irritable bowel syndrome and 8 inflammatory bowel disease patients were collected on site, aliquoted immediately after defecation and stored at -80 °C, -20 °C for 1 week, at +4°C or room temperature for 24 hours. Fecal transport swabs (FecalSwab, Copan) were collected and stored for 48-72 hours at room temperature. We used pyrosequencing of the 16S gene to investigate the stability of microbial communities. Alpha diversity did not differ between all storage methods and -80 °C, except for the fecal swabs. UPGMA clustering and principal coordinate analysis showed significant clustering by test subject (p < 0.001) but not by storage method. Bray-Curtis dissimilarity and (un)weighted UniFrac showed a significant higher distance between fecal swabs and -80 °C versus the other methods and -80 °C samples (p < 0.009). The relative abundance of Ruminococcus and Enterobacteriaceae did not differ between the storage methods versus -80 °C, but was higher in fecal swabs (p < 0.05). Storage up to 24 hours (at +4 °C or room temperature) or freezing at -20 °C did not significantly alter the fecal microbial community structure compared to direct freezing of samples from healthy subjects and patients with gastrointestinal disorders.
- Published
- 2015
- Full Text
- View/download PDF
12. Fecal microbial composition of ulcerative colitis and Crohn's disease patients in remission and subsequent exacerbation.
- Author
-
Edgar S Wills, Daisy M A E Jonkers, Paul H Savelkoul, Ad A Masclee, Marieke J Pierik, and John Penders
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Limited studies have examined the intestinal microbiota composition in relation to changes in disease course of IBD over time. We aimed to study prospectively the fecal microbiota in IBD patients developing an exacerbation during follow-up. DESIGN: Fecal samples from 10 Crohn's disease (CD) and 9 ulcerative colitis (UC) patients during remission and subsequent exacerbation were included. Active disease was determined by colonoscopy and/or fecal calprotectine levels. Exclusion criteria were pregnancy, antibiotic use, enema use and/or medication changes between consecutive samples. The microbial composition was assessed by 16S rDNA pyrosequencing. RESULTS: After quality control, 6,194-11,030 sequences per sample were available for analysis. Patient-specific shifts in bacterial composition and diversity were observed during exacerbation compared to remission, but overarching shifts within UC or CD were not observed. Changes in the bacterial community composition between remission and exacerbation as assessed by Bray-Curtis dissimilarity, were significantly larger in CD versus UC patients (0.59 vs. 0.42, respectively; p = 0.025). Thiopurine use was found to be a significant cause of clustering as shown by Principal Coordinate Analysis and was associated with decreases in bacterial richness (Choa1 501.2 vs. 847.6 in non-users; p
- Published
- 2014
- Full Text
- View/download PDF
13. Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients
- Author
-
Eelco C. Brand, Marjolein A.Y. Klaassen, Ranko Gacesa, Arnau Vich Vila, Hiren Ghosh, Marcel R. de Zoete, Dorret I. Boomsma, Frank Hoentjen, Carmen S. Horjus Talabur Horje, Paul C. van de Meeberg, Gonneke Willemsen, Jingyuan Fu, Cisca Wijmenga, Femke van Wijk, Alexandra Zhernakova, Bas Oldenburg, Rinse K. Weersma, Pieter Honkoop, Rutger J. Jacobs, Cyriel Y. Ponsioen, Nanne K.H. de Boer, Yasser A. Alderlieste, Margot A. van Herwaarden, Sebastiaan A.C. van Tuyl, Maurice W. Lutgens, C. Janneke van der Woude, Wout G.M. Mares, Daan B. de Koning, Joukje H. Bosman, Juda Vecht, Anneke M.P. de Schryver, Andrea E. van der Meulen-de Jong, Marieke J. Pierik, Paul J. Boekema, Robert J. Verburg, Bindia Jharap, Jeroen M. Jansen, Pieter C.F. Stokkers, Rutger Quispel, Nofel Mahmmod, Rachel L. West, Marleen Willems, Itta M. Minderhoud, Herma H. Fidder, Fiona D.M. van Schaik, Meike M.C. Hirdes, Nynke A. Boontje, Bart L.M. Müskens, Marielle J.L. Romberg-Camps, Center for Liver, Digestive and Metabolic Diseases (CLDM), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Biological Psychology, APH - Mental Health, APH - Methodology, and APH - Health Behaviors & Chronic Diseases
- Subjects
Male ,0301 basic medicine ,NETHERLANDS ,Siderophores ,Crohn's Disease ,Inflammatory bowel disease ,METAGENOMICS ,Feces ,0302 clinical medicine ,Risk Factors ,Twins, Dizygotic ,INDEX ,Crohn's disease ,MUCOSA ,Microbiota ,Confounding ,Gastroenterology ,Middle Aged ,Ulcerative colitis ,Preclinical ,Phenotype ,Female ,Inflammatory Breast Neoplasms ,030211 gastroenterology & hepatology ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Adult ,Prediagnostic ,GENETICS ,Family Studies ,digestive system ,Discordant Twin Design ,Young Adult ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,medicine ,Humans ,Ulcerative Colitis ,Microbiome ,Antigens, Bacterial ,Hepatology ,business.industry ,Twins, Monozygotic ,REMISSION ,medicine.disease ,Twin study ,digestive system diseases ,Gastrointestinal Microbiome ,POLYAMINES ,Cross-Sectional Studies ,030104 developmental biology ,Metagenomics ,Case-Control Studies ,Immunology ,business ,Prediction ,Body mass index - Abstract
Background & aims: It is currently unclear whether reported changes in the gut microbiome are cause or consequence of inflammatory bowel disease (IBD). Therefore, we studied the gut microbiome of IBD-discordant and -concordant twin pairs, which offers the unique opportunity to assess individuals at increased risk of developing IBD, namely healthy cotwins from IBD-discordant twin pairs. Methods: Fecal samples were obtained from 99 twins (belonging to 51 twin pairs), 495 healthy age-, sex-, and body mass index–matched controls, and 99 unrelated patients with IBD. Whole-genome metagenomic shotgun sequencing was performed. Taxonomic and functional (pathways) composition was compared among healthy cotwins, IBD-twins, unrelated patients with IBD, and healthy controls with multivariable (ie, adjusted for potential confounding) generalized linear models. Results: No significant differences were observed in the relative abundance of species and pathways between healthy cotwins and their IBD-twins (false discovery rate
- Published
- 2021
14. Exploring conditions for redistribution of anti-tumor necrosis factors to reduce spillage: A study on the quality of anti-tumor necrosis factor home storage
- Author
-
Marin J, de Jong, Marieke J, Pierik, Andy, Peters, Mark, Roemers, Veronique, Hilhorst, and Astrid, van Tubergen
- Subjects
Adult ,Male ,Quality Control ,Time Factors ,Drug Substitution ,Tumor Necrosis Factor-alpha ,Drug Storage ,Temperature ,Antibodies, Monoclonal ,Middle Aged ,Home Care Services ,Drug Utilization ,Injections ,Surveys and Questionnaires ,Humans ,Female ,Drug Packaging ,Aged - Abstract
Biologicals are potent drugs for immune-mediated inflammatory diseases. After discontinuation or switch of therapy, many patients have unused biological injectors left. This study aimed to evaluate potential redistribution of unused injectors to prevent spillage of these costly drugs by assessing (i) the quality of transport and home storage through the proportion of injectors stored within the recommended temperature range (2-8 °C) and (ii) acceptance of redistribution by patients.All golimumab users, irrespective of the indication, at Maastricht University Medical Center were eligible for inclusion. Patients received golimumab in a sealed bag containing a validated temperature sensor, measuring temperature every 5 min. Patients were asked to store their medication as usual. Deviations from the recommended range were defined as any duration below 0 °C and 30 min below 2 °C or above 8 °C. After 3 months, patients completed a questionnaire on their opinion towards potential redistribution of unused biologicals.Fifty patients (42.0% male, mean age 53.2 ± 14.3 years) received 276 injectors. The mean storage time was 30.9 ± 33.1 days. Only 11.6% of the injectors were stored within the recommended temperature range. In addition, 11.2% were stored 30 min below 0 °C and 33.2% were stored 1 week above 8 °C. Of all patients, 95% would accept redistributed medication when product quality is ensured.During transport and home storage, only one in eight biological injectors was stored within the recommended temperature range. This hinders redistribution of unused injectors but also raises concern regarding drug effectiveness in immune-mediated inflammatory disease patients.
- Published
- 2017
15. [Chronic diarrhoea due to microscopic colitis: awareness pays]
- Author
-
Bas P M, Verhaegh, Maarten A, van Dijk, Danny, Goudkade, Marieke J, Pierik, and Ad A M, Masclee
- Subjects
Colitis, Microscopic ,Diarrhea ,Treatment Outcome ,Biopsy ,Incidence ,Anti-Inflammatory Agents, Non-Steroidal ,Humans ,Female ,Awareness ,Middle Aged ,Aged ,Netherlands - Abstract
The incidence of microscopic colitis (MC) in The Netherlands is increasing, yet the numbers are low compared to other countries. Awareness is likely to play a role. We describe two cases to illustrate the benefit of MC awareness among physicians and pathologists. In a 45-year-old female who presented with chronic diarrhoea, no cause could be identified despite extensive examinations in other hospitals. A biopsy revision, performed in our centre, revealed MC. Treatment with budesonide was immediately effective. A 76-year-old female with chronic diarrhoea was also diagnosed with MC. Because a relationship with NSAID use was suspected, the drug was withdrawn and the diarrhoea resolved. These cases illustrate that awareness of MC might accelerate the diagnosis of patients with chronic diarrhoea, consequently enabling the prescription of oral budesonide, a highly effective treatment. Some drugs are associated with an increased risk of MC. Withdrawal of these drugs could be another successful treatment strategy.
- Published
- 2016
16. Implementation of quality controls is essential to prevent batch effects in breathomics data and allow for cross-study comparisons.
- Author
-
Georgios Stavropoulos, Daisy M A E Jonkers, Zlatan Mujagic, Ger H Koek, Ad A M Masclee, Marieke J Pierik, Jan W Dallinga, Frederik-Jan Van Schooten, and Agnieszka Smolinska
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.